SCHEMBL1270149

SCHEMBL1270149

Nc1cc(=O)c2ccccc2[nH]c1=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 3/20 0.56
GAA P10253 3/20 0.56
KDM4E B2RXH2 10/20 0.53
ALDH1A1 P00352 5/20 0.53
PARP1 P09874 4/20 0.53
HSD17B10 Q99714 3/20 0.53
LMNA P02545 3/20 0.53
KMT2A Q03164 3/20 0.53
MEN1 O00255 2/20 0.53
TNKS O95271 1/20 0.53
GPR3 P46089 1/20 0.53
BLM P54132 1/20 0.53
PMP22 Q01453 1/20 0.53
PARP15 Q460N3 1/20 0.53
TNKS2 Q9H2K2 1/20 0.53
HPGD P15428 4/20 0.53
CTSV O60911 3/20 0.53
CTSL P07711 3/20 0.53
TUBB4A P04350 1/20 0.53
TP53 P04637 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10070259 0.80 CYP1A2 (0.60) CYP1A2GAAKDM4EALDH1A1PARP1
SCHEMBL2639080 0.77 DAO (0.61) CYP1A2GAAKDM4EALDH1A1PARP1
SCHEMBL9274411 0.77 CYP1A2 (0.51) CYP1A2GAAKDM4EALDH1A1PARP1
SCHEMBL7811758 0.77 LMNA (0.60) KDM4EALDH1A1PARP1LMNAKMT2A
SCHEMBL7339379 0.77 PARP1 (0.57) CYP1A2KDM4EALDH1A1PARP1HSD17B10
SCHEMBL30114776 0.76 DAO (0.60) KDM4EALDH1A1PARP1HSD17B10KMT2A
SCHEMBL545302 0.76 DAO (0.60) KDM4EALDH1A1PARP1HSD17B10KMT2A
SCHEMBL31378654 0.74 DAO (0.65) CYP1A2KDM4EALDH1A1PARP1HSD17B10
SCHEMBL6343134 0.74 KDM4E (0.62) CYP1A2GAAKDM4EALDH1A1PARP1
SCHEMBL7431309 0.73 CYP1A2 (0.56) CYP1A2GAAKDM4EALDH1A1PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0644878-B1 2,5-DIOXO-2,5-DIHYDRO-1H-BENZ b]AZEPINES AS NMDA RECEPTOR ANTAGONISTS ASTRAZENECA AB (SE) 2001-09-12 EP claimed
US-5492905-A NERVOUS SYSTEM DISORDERS ZENECA LIMITED (GB) 1996-02-20 US claimed
EP-0644878-A1 2,5-DIOXO-2,5-DIHYDRO-1H-BENZ b]AZEPINES AS NMDA RECEPTOR ANTAGONISTS ZENECA LIMITED (GB) 1995-03-29 EP claimed
WO-1993025534-A1 2,5-DIOXO-2,5-DIHYDRO-1H-BENZ[b]AZEPINES AS NMDA RECEPTOR ANTAGONISTS ZENECA LIMITED (GB) 1993-12-23 WO claimed
US-7888345-B2 Benzaepinones as sodium channel blockers MERCK SHARP & DOHME CORP. (US) 2011-02-15 US disclosed
US-20090181946-A1 Benzaepinones as Sodium Channel Blockers MERCK SHARP & DOHME CORP. 2009-07-16 US disclosed
EP-2032539-A2 BENZAZEPINONES AS SODIUM CHANNEL BLOCKERS Merck & Co., Inc. (US) 2009-03-11 EP disclosed
WO-2007145922-A2 BENZAZEPINONES AS SODIUM CHANNEL BLOCKERS MERCK & CO., INC. (US) 2007-12-21 WO disclosed
EP-0644878-B1 2,5-DIOXO-2,5-DIHYDRO-1H-BENZ b]AZEPINES AS NMDA RECEPTOR ANTAGONISTS ASTRAZENECA AB (SE) 2001-09-12 EP disclosed
US-5712272-A TREATMENT OF NEUROLOGICAL DISORDERS WITH BENZ(B)AZEPINE COMPOUNDS ZENECA LIMITED (GB) 1998-01-27 US disclosed
US-5654295-A NEUROLOGICAL DISORDERS; BENZ(B0AZEPINE COMPOUNDS ZENECA LIMITED (GB) 1997-08-05 US disclosed
US-5492905-A NERVOUS SYSTEM DISORDERS ZENECA LIMITED (GB) 1996-02-20 US disclosed
EP-0644878-A1 2,5-DIOXO-2,5-DIHYDRO-1H-BENZ b]AZEPINES AS NMDA RECEPTOR ANTAGONISTS ZENECA LIMITED (GB) 1995-03-29 EP disclosed
WO-1993025534-A1 2,5-DIOXO-2,5-DIHYDRO-1H-BENZ[b]AZEPINES AS NMDA RECEPTOR ANTAGONISTS ZENECA LIMITED (GB) 1993-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181946-A1 Benzaepinones as Sodium Channel Blockers TRPV1, TRPA1, KCNN1 CYP1A2 1501/4885GAA 1196/4885KDM4E 2597/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.